Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: J Thorac Oncol. 2019 Oct 9;14(12):2084–2096. doi: 10.1016/j.jtho.2019.09.014

Figure 4. Indicative and prognostic performance of high CMTM6 and PD-L1 co-expression.

Figure 4.

(a)-(c) OS according to PD-L1 expression alone in the tumor compartment (a), the stromal compartment (b), and the CD68 compartment (c) in patients treated with single-agent PD-1 axis blockade; (d)-(d) OS in patients with high CMTM6 and PD-L1 co-expression in the tumor compartment (d), the stromal compartment (e), and the CD68 compartment (f) in patients treated with single-agent PD-1 axis blockade; (g)-(i) OS in patients with high CMTM6 and PD-L1 co-expression in the tumor compartment (g), the stromal compartment (h), and the CD68 compartment (i) in patients non-treated with immunotherapy